Ampio Pharmaceuticals (AMPE) +18.1% premarket after announcing an agreement with India-based Syngene to manufacture a combination product, Zertane-ED, to treat certain male sexual dysfunctions. The product will be used in Phase 3 trials in South Korea with AMPE partner Daewoong, which will finance and conduct the trials.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs